Elepsia^® XR is a novel, once-a-day formulation of Levetiracetam, a commercially successful anti-epileptic agent.The average daily dose of Levetiracetam in majority of patients is in the range of 2000 mg to 3000 mg per day. However, only 500 mg and 750 mg strength once-a-day tablet formulations are available in the market today, which makes it necessary for patients to take multiple pills in a day.

Elepsia^® XR is designed as higher strengths of 1000 mg and 1500 mg once-a-day tablet for reducing pill burden. Although the dose per tablet is high, the proprietary Wrap Matrix™ Technology helps Elepsia^® XR tablets to be formulated with less excipients, thereby making the tablet compact and better acceptable for patients.

Elepsia^® XR represents a new therapeutic option to reduce pill burden and improve patient compliance. Elepsia^® XR is protected by composition and dose specific patents granted in US.

The New Drug Application (NDA) for Elepsia^® XR has been approved by the US FDA and commercialized in the US market by Tripoint Therapeutics LLC.